MESO: Mesoblast Ltd - ADR Company Profile & Statistics

About

Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Info & Links

CEO

Silviu Itescu

Headquarters

LEVEL 38, 55 COLLINS STREET
MELBOURNE, VICTORIA, C3 3000, AUSTRALIA

Auditor

PricewaterhouseCoopers

Share holders

Employees

Mesoblast Ltd - ADR Statistics

Valuation Measures

Market Capitalization²

1.46B

Enterprise Value

1.51B

Enterprise Value/EBITDA(ttm)

-37.27

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

Price to Book(mrq)

2.80

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

-199.81%

Operating Margin(ttm)

Profit Margin(ttm)

-805.32%

Return on Equity(ttm)

Return on Invested Capital(ttm)

-9.56%

Return on Assets(ttm)

Income Statement

Revenue(ttm)

5.37M

Revenue Per Share(ttm)

0.05

Gross Profit(ttm)

-14.47M

EBITDA(ttm)³

-40.59M

Net Income Available to Common(ttm)

-57.40M

Diluted EPS(ttm)

Share Statistics

Beta (5Y Monthly)

3.54

52-Week Change

370.59%

S&P 500 52-Week Change

26.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

114.18M

Dividend Yield

0.00%

Float⁴

92.71M

% Held by Insiders

18.80%

% Held by Institutions

1.43%

Balance Sheet

Total Cash(mrq)

62.96M

Total Cash Per Share(mrq)

0.55

Total Debt(mrq)

114.34M

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

Quick Ratio(mrq)

1.18%

Book Value Per Share(mrq)

Cash Flow

Operating Cash Flow Per Share(ytd)

Free Cash Flow(ytd)

0.00

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

MESO

Mesoblast Ltd - ADR

Mesoblast Ltd - ADR Profile